The N-terminal alanine-extended GLP-1/IgG-Fc fusion protein confers resistance to DPP-IV and reduces serum glucose level in db/db mice

Regulatory Peptides

Volumn 170, Issue 1-3, 2011, Pages 1-3

  Chung, Hye Shin ^a,b   Oh, Ji Yeon ^b   Yoo, Seung Bum ^a   Lee, Sang Mee ^a   Cho, Heung Soo ^a  

^a Alteogen Inc   (South Korea)

^b Hannam University   (South Korea)

Author keywords

Dipeptidyl peptidase IV (DPPIV); Glucagon like peptide 1 (GLP 1); IgG Fc fusion; Type 2 diabetes

Indexed keywords

ALANINE; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 IMMUNOGLOBULIN HEAVY CHAIN FUSION PROTEIN; GLUCOSE; GLYCINE; HYBRID PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INHIBITION; GLUCOSE BLOOD LEVEL; IN VIVO STUDY; INSULIN RESISTANCE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; BLOOD GLUCOSE; DIPEPTIDYL PEPTIDASE 4; GLUCAGON-LIKE PEPTIDE 1; HALF-LIFE; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MICE; MICE, INBRED NOD; MOLECULAR SEQUENCE DATA; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; SEQUENCE ANALYSIS, PROTEIN;

MUS;

EID: 79959741675     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2011.05.002     Document Type: Article

References (11)

1. Hui H., Zhao X., Perfetti R. Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes. Diabetes Metab Res Rev 2005, 21:313-331.
2. Kieffer T.J., Habener J.F. The glucagon-like peptides. Endocr Rev 1999, 20:876-913.
3. Green B.D., Mooney M.H., Gault V.A., et al. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity. J Endocrinol 2004, 180:379-388.
4. O'Harte F.P., Mooney M.H., Lawlor A., Flatt P.R. N-terminally modified glucagon-like peptide-1(7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo. Biochim Biophys Acta 2000, 1474:13-22.
5. Deacon C.F., Knudsen L.B., Madsen K., Wiberg F.C., Jacobsen O., Holst J.J. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 1998, 41:271-278.
6. Xiao Q., Giguere J., Parisien M., et al. Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry 2001, 40:2860-2869.
7. Baggio L.L., Huang Q., Brown T.J., Drucker D.J. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 2004, 53:2492-2500.
8. Kumar M., Hunag Y., Glinka Y., Prud'homme G.J., Wang Q. Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice. Gene Ther 2007, 14:162-172.
9. Wang Q., Chen K., et al. Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. PLoS One 2010, 5(9):e12734.
10. Oh J.-Y., Lee C.W., Jang S.-H., Yoo S.-B., Chung H.-S. Novel DPP-IV-resistant analogs of GLP-1: the N-terminal extension of GLP-1 by a single amino acid. Bull Korean Chem Soc 2009, 30:2471-2474.
11. Smith R.E., Reynolds C.J., Elder E.A. The evolution of proteinase substrates with special reference to dipeptidylpeptidase IV. Histochem J 1992, 24:637-647.